Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels

Pharmacogenomics

Volumn 14, Issue 2, 2013, Pages 215-223

  Conrado, Daniela J ^a,b   Rogers, Hobart L ^a   Zineh, Issam ^a   Pacanowski, Michael A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

CYP450 metabolism; drug labels; drug drug interaction; FDA; genotype based dosing; pharmacogenetics

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; BOSENTAN; CARVEDILOL; CELECOXIB; CILOSTAZOL; CITALOPRAM; CLOBAZAM; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DIAZEPAM; ILOPERIDONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PAROXETINE; PHENYTOIN; PIMOZIDE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TETRABENAZINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

AGRANULOCYTOSIS; ALTERNATIVE MEDICINE; ARTICLE; ATAXIA; BLEEDING; BLOOD PRESSURE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INFORMATION; DRUG LABELING; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GENE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC DIFFERENCE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IN VIVO STUDY; INTESTINE PERFORATION; INTRACARDIAC THROMBOSIS; LIVER INJURY; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHADENOPATHY; MENTAL DISEASE; NYSTAGMUS; PHARMACOGENOMICS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; STOMACH PERFORATION; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TOXIC HEPATITIS; TRANSIENT ISCHEMIC ATTACK; ULCER; UNITED STATES;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DRUG APPROVAL; DRUG INTERACTIONS; DRUG LABELING; ENZYME INHIBITORS; HUMANS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872509051     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.203     Document Type: Article

References (44)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients - a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998). (Pubitemid 28193431)
2. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289(9), 1107-1116 (2003). (Pubitemid 37430324)
3. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289(13), 1652-1658 (2003). (Pubitemid 37430270)
4. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7(6), 889-908 (2006). (Pubitemid 44446737)
5. Zhang W, Roederer MW, Chen W-Q, Fan L, Zhou H-H. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 13(2), 223-231 (2012).
6. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81(2), 298-304 (2007). (Pubitemid 46174829)
7. Huang SM, Strong JM, Zhang L et al. New era in drug interaction evaluation. US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48(6), 662-670 (2008). (Pubitemid 351713150)
8. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001). (Pubitemid 32385908)
9. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002). (Pubitemid 34223859)
10. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12(3), 251-263 (2002). (Pubitemid 34596790)
11. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
12. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001). (Pubitemid 33063150)
13. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome-P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic-chemicals - studies with liver-microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994). (Pubitemid 24229655)
14. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin. Pharmacokinet. 37(Suppl. 2), 53-59 (1999). (Pubitemid 30171187)
15. Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br. J. Clin. Pharmacol. 69(1), 27-37 (2010).
16. Brockmoller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72(4), 438-452 (2002). (Pubitemid 35178869)
17. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin. Lab. Med. 28(4), 619-626 (2008).
18. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
19. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47(1), 75-85 (2006). (Pubitemid 43017126)
20. Mas S, Llerena A, Saiz J, Bernardo M, Lafuente A. Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13(15), 1773-1782 (2012).
21. Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J. Cardiovasc. Pharmacol. Ther. 6(3), 255-260 (2001). (Pubitemid 34296588)
22. Shapiro E, Shapiro AK, Fulop G et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry 46(8), 722-730 (1989). (Pubitemid 19198099)
23. Rogers HL, Bhattaram A, Zineh I et al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the US Food and Drug Administration's new dosing recommendations. J. Clin. Psychiatry 73(9), 1187-1190 (2012).
24. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18(1), 84-112 (1998). (Pubitemid 28059007)
25. Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 17(4), 550-554 (2012).
26. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin. Pharmacokinet. 47(2), 75-89 (2008).
27. Boyer EW, Shannon M. The serotonin syndrome. N. Engl. J. Med. 352(11), 1112-1120 (2005).
28. Marcus FI. Drug interactions with amiodarone. Am. Heart. J. 106(4 Pt 2), 924-930 (1983). (Pubitemid 13010827)
29. Binkhorst L, Van Gelder T, Mathijssen RH. Individualization of tamoxifen treatment for breast carcinoma. Clin. Pharmacol. Ther. 92(4), 431-433 (2012).
30. Sadhasivam S, Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics 13(15), 1719-1740 (2012).
31. US FDA. Center for Drug Evaluation and Research. Clinical pharmacogenomics: premarketing evaluation in early phase clinical studies (2011). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM243702.pdf
32. US FDA. Center for Drug Evaluation and Research. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (2012). www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
33. Micromedex® 2.0. www.thomsonhc.com/home/dispatch
34. University of Washington. Metabolism & Transport Drug Interaction Database (2012). www.druginteractioninfo.org/Home.aspx
35. PharmGKB. The Pharmacogenomics Knowledge Base (2012). www.pharmgkb.org
36. Flockhart DA; Indiana University School of Medicine. Drug Interactions: Cytochrome P450 Drug Interaction Table (2011). http://medicine.iupui.edu/ clinpharm/ddis
37. US FDA. Drugs@FDA: FDA Approved Drug Products (2012). www.accessdata.fda.gov/scripts/cder/drugsatfda
38. NIH. DailyMed (2012). http://dailymed.nlm.nih.gov/
39. Actelion Pharms Ltd Tracleer® (bosentan) Tablets. US Labeling Information (2012). www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021290s022lbl.pdf
40. US FDA. Code of Federal Regulations Title 21: Food and Drugs. Revised as of April 1, 2011. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?fr=201.56
41. Teva Pharmaceuticals Orap® (pimozide) Tablets. US Labeling Information (2011). www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 017473s046lbl.pdf
42. Valeant Pharmaceuticals Xenazine® (tetrabenazine) Tablets. US Labeling Information (2011). www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021894s004lbl.pdf
43. Prestwick Pharmaceuticals Inc. Xenazine (Tetrabenazine) Tablets. FDA Drug Approval Package. Clinical Pharmacology Biopharmaceutics Review(s) (2008). www.accessdata.fda.gov/drugsatfda-docs/nda/2008/021894s000TOC.cfm
44. Sanofi Aventis Plavix® (clopidrogrel). US Labeling Information (2011). www.accessdata.fda.gov/drugsatfda-docs/label/2011/020839s055lbl.pdf